Division of Neurosurgery, Department of Clinical Neurosciences, University of Calgary, Foothills Hospital 12th Floor 1403-29 ST NW #1195, Calgary, AB, T2N 2T9, Canada.
J Neurooncol. 2011 Apr;102(2):255-60. doi: 10.1007/s11060-010-0307-5. Epub 2010 Jul 21.
Epigenetic silencing of the MGMT gene through promoter methylation correlates with improved survival in Glioblastoma Multiforme (GBM) patients receiving concurrent chemoradiotherapy. Although the clinical benefit is primarily seen in patients with methylated MGMT promoter, some unmethylated patients also respond to Temozolomide. One possible explanation may be intratumoral heterogeneity. This study was designed to assess the methylation status of the MGMT promoter in different areas of GBM and determine if methylation status varied depending on the fixation technique (paraffin-embedding versus fresh frozen) used to store tissue. Using intraoperative navigation, biopsies were obtained from three distinct regions: the enhancing outer area, the non-enhancing inner core, and an area immediately outside the enhancing region. Only patients with GBM were included for evaluation and analysis. Samples taken from each area were divided with half stored by flash freezing and the other half stored using paraffin fixation. Methylation Specific-PCR (MS-PCR) was used for analysis of MGMT promoter methylation. Thirteen patients were included. Ten were male with a median age of 62 years. In each patient, samples were taken from the enhancing rim and the necrotic centre. However, it was not considered safe or feasible to obtain samples from the area immediately adjacent to the enhancing tumor rim in one case. All patients were homogeneous for methylation status throughout their tumor and tissue taken adjacent to it when frozen tissue was used. However, four patients had discrepancies in the MGMT promoter status between the frozen and paraffin-embedded blocks and one patient was not homogeneous within the tumor when paraffin-embedded tissue was used. MGMT promoter methylation status was homogeneous in all GBM tumors. Our observation that methylation status varied depending if the DNA was extracted from paraffin-embedded versus frozen tissue is concerning. Although the reason for this is unclear, we postulate that the timing from resection to fixation or the process of fixation itself may potentially alter methylation status in paraffin-embedded tumors.
MGMT 基因启动子甲基化导致的表观遗传沉默与接受同步放化疗的多形性胶质母细胞瘤 (GBM) 患者的生存改善相关。尽管在甲基化 MGMT 启动子的患者中主要观察到临床获益,但一些未甲基化的患者也对替莫唑胺有反应。一种可能的解释可能是肿瘤内异质性。本研究旨在评估 GBM 不同区域 MGMT 启动子的甲基化状态,并确定甲基化状态是否因用于储存组织的固定技术(石蜡包埋与新鲜冷冻)而异。使用术中导航,从三个不同区域获取活检:增强的外区、非增强的核心区和增强区外的一个区域。只有 GBM 患者被纳入评估和分析。从每个区域采集的样本分为一半通过快速冷冻保存,另一半通过石蜡固定保存。使用甲基化特异性 PCR(MS-PCR)分析 MGMT 启动子甲基化。纳入了 13 名患者。10 名男性,中位年龄为 62 岁。在每个患者中,均从增强环和坏死中心采集样本。然而,在一个病例中,考虑到从紧邻增强肿瘤边缘的区域获取样本是不安全或不可行的。当使用冷冻组织时,所有患者的肿瘤及其相邻组织的甲基化状态在整个肿瘤中均具有均一性。然而,在 4 名患者中,冷冻和石蜡包埋块之间的 MGMT 启动子状态存在差异,在使用石蜡包埋组织时,一名患者的肿瘤内存在不均一性。所有 GBM 肿瘤的 MGMT 启动子甲基化状态均具有均一性。我们观察到,DNA 是从石蜡包埋组织还是冷冻组织中提取的,其甲基化状态会有所不同,这令人担忧。尽管原因尚不清楚,但我们推测,从切除到固定的时间或固定本身的过程可能会改变石蜡包埋肿瘤中的甲基化状态。